DK168322B1 - Ethanoliske opløsninger af oxazaphosphoriner med forbedret stabilitet - Google Patents
Ethanoliske opløsninger af oxazaphosphoriner med forbedret stabilitet Download PDFInfo
- Publication number
- DK168322B1 DK168322B1 DK359387A DK359387A DK168322B1 DK 168322 B1 DK168322 B1 DK 168322B1 DK 359387 A DK359387 A DK 359387A DK 359387 A DK359387 A DK 359387A DK 168322 B1 DK168322 B1 DK 168322B1
- Authority
- DK
- Denmark
- Prior art keywords
- solutions
- oxazaphosphorins
- ethanol
- cyclophosphamide
- preparation
- Prior art date
Links
- ZZVDXRCAGGQFAK-UHFFFAOYSA-N 2h-oxazaphosphinine Chemical class N1OC=CC=P1 ZZVDXRCAGGQFAK-UHFFFAOYSA-N 0.000 title claims abstract description 23
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 37
- 125000001340 2-chloroethyl group Chemical group [H]C([H])(Cl)C([H])([H])* 0.000 claims abstract description 7
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims abstract description 3
- 239000001257 hydrogen Substances 0.000 claims abstract description 3
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 3
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims abstract description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims abstract description 3
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims description 17
- 229960004397 cyclophosphamide Drugs 0.000 claims description 17
- 229960001101 ifosfamide Drugs 0.000 claims description 8
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 claims description 8
- -1 2-methanesulfonyloxyethyl Chemical group 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 abstract description 15
- 238000000034 method Methods 0.000 abstract description 6
- 239000000243 solution Substances 0.000 description 33
- 239000013543 active substance Substances 0.000 description 8
- 239000000203 mixture Substances 0.000 description 7
- 238000003860 storage Methods 0.000 description 6
- 230000015556 catabolic process Effects 0.000 description 4
- 238000006731 degradation reaction Methods 0.000 description 4
- 238000004090 dissolution Methods 0.000 description 4
- 150000004682 monohydrates Chemical class 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 239000013078 crystal Substances 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 230000000474 nursing effect Effects 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 2
- 239000003708 ampul Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 238000002845 discoloration Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000003978 infusion fluid Substances 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- CTPDSKVQLSDPLC-UHFFFAOYSA-N 2-(oxolan-2-ylmethoxy)ethanol Chemical compound OCCOCC1CCCO1 CTPDSKVQLSDPLC-UHFFFAOYSA-N 0.000 description 1
- PMVSDNDAUGGCCE-TYYBGVCCSA-L Ferrous fumarate Chemical compound [Fe+2].[O-]C(=O)\C=C\C([O-])=O PMVSDNDAUGGCCE-TYYBGVCCSA-L 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- MRIMWDXKBILRPB-UHFFFAOYSA-N O=P1NCCCO1 Chemical compound O=P1NCCCO1 MRIMWDXKBILRPB-UHFFFAOYSA-N 0.000 description 1
- 239000012891 Ringer solution Substances 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- 239000004086 alkylating cytostatic agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 239000000824 cytostatic agent Substances 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Substances [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940068886 polyethylene glycol 300 Drugs 0.000 description 1
- 229940068918 polyethylene glycol 400 Drugs 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 229960004063 propylene glycol Drugs 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Detergent Compositions (AREA)
- Cosmetics (AREA)
- Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
- Paper (AREA)
- Carbon And Carbon Compounds (AREA)
- Food Preservation Except Freezing, Refrigeration, And Drying (AREA)
- Inks, Pencil-Leads, Or Crayons (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE3623369 | 1986-07-11 | ||
| DE3623369 | 1986-07-11 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| DK359387D0 DK359387D0 (da) | 1987-07-10 |
| DK359387A DK359387A (da) | 1988-01-12 |
| DK168322B1 true DK168322B1 (da) | 1994-03-14 |
Family
ID=6304930
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK359387A DK168322B1 (da) | 1986-07-11 | 1987-07-10 | Ethanoliske opløsninger af oxazaphosphoriner med forbedret stabilitet |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US4952575A (enExample) |
| EP (1) | EP0254902B1 (enExample) |
| JP (1) | JPS6323888A (enExample) |
| KR (1) | KR880001282A (enExample) |
| AT (1) | ATE66609T1 (enExample) |
| AU (1) | AU598282B2 (enExample) |
| CA (1) | CA1289886C (enExample) |
| DE (2) | DE3772482D1 (enExample) |
| DK (1) | DK168322B1 (enExample) |
| ES (1) | ES2038623T3 (enExample) |
| FI (1) | FI86690C (enExample) |
| GR (1) | GR3002618T3 (enExample) |
| IE (1) | IE59897B1 (enExample) |
| IL (1) | IL83141A (enExample) |
| PT (1) | PT85293B (enExample) |
| ZA (1) | ZA875059B (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5051257A (en) * | 1989-05-09 | 1991-09-24 | Pietronigro Dennis D | Antineoplastic solution and method for treating neoplasms |
| RO113611B1 (ro) * | 1990-08-03 | 1998-09-30 | Asta Pharma Ag | Preparate solide de ifosfamida, administrate oral si procedeu de obtinere |
| US5227373A (en) * | 1991-10-23 | 1993-07-13 | Bristol-Myers Squibb Co. | Lyophilized ifosfamide compositions |
| DE59813853D1 (de) * | 1997-10-13 | 2007-02-01 | Stada Arzneimittel Ag | Flüssige darreichungsformen oxazaphosphorinhaltiger pharmazeutischer produkte |
| US7205404B1 (en) * | 1999-03-05 | 2007-04-17 | Metabasis Therapeutics, Inc. | Phosphorus-containing prodrugs |
| AUPQ849900A0 (en) * | 2000-06-30 | 2000-07-27 | Dbl Australia Pty Ltd. | Injectable composition |
| US6613927B1 (en) | 2002-02-08 | 2003-09-02 | American Pharmaceutical Partners, Inc. | Sterile lyophilized ifosfamide and associated methods |
| CN1694713A (zh) * | 2002-09-05 | 2005-11-09 | 印度血清及疫苗有限公司 | oxazaphosphorine和美司钠的液态稳定组合物 |
| US7199111B2 (en) * | 2002-12-02 | 2007-04-03 | Bharat Serums & Vaccines Ltd. | Aqueous ifosfamide compositions for parenteral administration and a process for their preparations |
| CA2580202A1 (en) * | 2004-09-13 | 2006-03-23 | Bharat Serums & Vaccines Ltd. | Stable emulsion compositions for intravenous administration having antimicrobial preservative efficacy |
| US10449210B2 (en) | 2014-02-13 | 2019-10-22 | Ligand Pharmaceuticals Inc. | Prodrug compounds and their uses |
| CN106456654A (zh) * | 2014-05-09 | 2017-02-22 | 奥罗医学制药有限公司 | 环磷酰胺液体浓缩制剂 |
| US9994600B2 (en) | 2014-07-02 | 2018-06-12 | Ligand Pharmaceuticals, Inc. | Prodrug compounds and uses therof |
| US10849916B2 (en) | 2014-07-11 | 2020-12-01 | Dr. Reddys Laboratories Limited | Stable liquid formulations of cyclophosphamide and its impurities |
| WO2016005962A2 (en) | 2014-07-11 | 2016-01-14 | Dr. Reddy’S Laboratories Limited | Stable liquid formulations of cyclophosphamide and processes |
| US10993952B2 (en) * | 2015-02-16 | 2021-05-04 | Leiutis Pharmaceuticals Pvt. Ltd. | Stable ready to use cyclophosphamide liquid formulations |
| RU2020126177A (ru) | 2018-01-09 | 2022-02-10 | Лиганд Фармасьютикалз, Инк. | Ацетальные соединения и их терапевтическое применение |
| WO2022038072A1 (en) * | 2020-08-17 | 2022-02-24 | Sandoz Ag | Parenteral pharmaceutical composition comprising cyclophosphamide and a mixture of liquids |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3530147A1 (de) * | 1985-08-23 | 1987-02-26 | Bayer Ag | Verwendung von diazaphosphorinen zur bekaempfung von endoparasiten |
-
1987
- 1987-07-03 EP EP87109559A patent/EP0254902B1/de not_active Expired - Lifetime
- 1987-07-03 AT AT87109559T patent/ATE66609T1/de not_active IP Right Cessation
- 1987-07-03 DE DE8787109559T patent/DE3772482D1/de not_active Expired - Lifetime
- 1987-07-03 ES ES198787109559T patent/ES2038623T3/es not_active Expired - Lifetime
- 1987-07-03 DE DE19873722043 patent/DE3722043A1/de not_active Withdrawn
- 1987-07-07 JP JP62167976A patent/JPS6323888A/ja active Granted
- 1987-07-09 PT PT85293A patent/PT85293B/pt unknown
- 1987-07-09 IL IL83141A patent/IL83141A/xx not_active IP Right Cessation
- 1987-07-10 DK DK359387A patent/DK168322B1/da not_active IP Right Cessation
- 1987-07-10 CA CA000541835A patent/CA1289886C/en not_active Expired - Lifetime
- 1987-07-10 ZA ZA875059A patent/ZA875059B/xx unknown
- 1987-07-10 FI FI873064A patent/FI86690C/fi not_active IP Right Cessation
- 1987-07-10 AU AU75549/87A patent/AU598282B2/en not_active Expired
- 1987-07-10 IE IE186787A patent/IE59897B1/en not_active IP Right Cessation
- 1987-07-11 KR KR1019870007481A patent/KR880001282A/ko not_active Ceased
-
1989
- 1989-02-06 US US07/307,230 patent/US4952575A/en not_active Expired - Lifetime
-
1991
- 1991-08-29 GR GR91401184T patent/GR3002618T3/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PT85293B (pt) | 1990-03-30 |
| EP0254902A3 (en) | 1988-08-03 |
| AU7554987A (en) | 1988-01-14 |
| PT85293A (de) | 1987-08-01 |
| JPS6323888A (ja) | 1988-02-01 |
| GR3002618T3 (en) | 1993-01-25 |
| CA1289886C (en) | 1991-10-01 |
| IL83141A0 (en) | 1987-12-31 |
| AU598282B2 (en) | 1990-06-21 |
| FI86690C (fi) | 1992-10-12 |
| DE3772482D1 (de) | 1991-10-02 |
| EP0254902B1 (de) | 1991-08-28 |
| FI873064L (fi) | 1988-01-12 |
| DK359387D0 (da) | 1987-07-10 |
| IL83141A (en) | 1992-11-15 |
| FI86690B (fi) | 1992-06-30 |
| DE3722043A1 (de) | 1988-01-14 |
| FI873064A0 (fi) | 1987-07-10 |
| ES2038623T3 (es) | 1993-08-01 |
| KR880001282A (ko) | 1988-04-22 |
| IE871867L (en) | 1988-01-11 |
| EP0254902A2 (de) | 1988-02-03 |
| DK359387A (da) | 1988-01-12 |
| IE59897B1 (en) | 1994-04-20 |
| US4952575A (en) | 1990-08-28 |
| ATE66609T1 (de) | 1991-09-15 |
| ZA875059B (en) | 1988-02-24 |
| JPH0543711B2 (enExample) | 1993-07-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK168322B1 (da) | Ethanoliske opløsninger af oxazaphosphoriner med forbedret stabilitet | |
| JPS62242618A (ja) | 水銀含有防腐剤を安定化した眼炎治療薬 | |
| BG107788A (bg) | Фармацевтични състави на nmda рецепторен агонист | |
| PT90124B (pt) | Processo para a preparacao de composicoes farmaceuticas de piroxicamo em solucoes aquosas | |
| CZ281142B6 (cs) | Roztoky léčiva se zvýšenou stabilitou a bez účinků poškozujících tkáň a způsob jejich přípravy | |
| JP2025506895A (ja) | 低吸着性グリブリドキット、製剤および方法 | |
| RU2157687C2 (ru) | Фармацевтические составы для парентерального введения, содержащие n-{4-[2-(1,2,3,4-тетрагидро-6,7-диметокси-2-изохинолинил)-этил]-фенил]-9,1 0-дигидро-5-метокси-9-оксо-4-акридинкарбоксамид | |
| KR100366130B1 (ko) | 항과혈당증작용을지닌약제 | |
| TWI260224B (en) | Pharmaceutical compositions for the treatment of tumor diseases | |
| JP2013529205A (ja) | 注射用イブプロフェン医薬組成物 | |
| PT90356B (pt) | Processo para a preparacao de composicoes farmaceuticas contendo solucoes aquosas de pentamidina | |
| RU2272623C2 (ru) | РАСТВОР ТЕТРАГИДРАТА МОНОНАТРИЕВОЙ СОЛИ N-[O-(п-ПИВАЛОИЛОКСИБЕНЗОЛСУЛЬФОНИЛАМИНО)БЕНЗОИЛ]ГЛИЦИНА И ГОТОВАЯ ЛЕКАРСТВЕННАЯ ФОРМА НА ЕГО ОСНОВЕ | |
| AU2007271431A1 (en) | Aqueous pharmaceutical formulation of 4-[((4-carboxybutyl)-{2-[(4-phenethyl-benzyl)oxy]-phenethyl}amino)methyl] benzoic acid | |
| JPH03130226A (ja) | １つより多いエチレンイミン基を有する抗新生物性化合物用の安定な製薬学的配合及び方法 | |
| HU220867B1 (en) | Pharmaceutical compositions as a solution, containing bis-triazole derivatives and process for producing them | |
| WO2007008350A1 (en) | Pharmaceutical formulations of endo-n-(9- methyl-9-azabicyclo[3 .3.1]non-3-yl)-1-methyl-1h-indazole-3-carboxamide hydrochloride | |
| JP2002080361A (ja) | Ｎ−［ｏ−（ｐ−ピバロイルオキシベンゼンスルホニルアミノ）ベンゾイル］グリシン・モノナトリウム塩・４水和物含有溶液および製剤 | |
| DK155144B (da) | Fremgangsmaade til fremstilling af stabile oploesninger af en blanding af hydrogenerede ergotalkaloider og heparin | |
| FR2714291A1 (fr) | Application des dérivés de la pyridone à titre de médicaments anesthésiques. | |
| JPH02500671A (ja) | 抗乾癬医薬組成物の調製方法 | |
| AT390881B (de) | Verfahren zur herstellung von pharmazeutischen loesungen von oxazaphosphorinen mit verbesserter stabilitaet | |
| WO2024257125A1 (en) | Injectable compositions of flecainide | |
| JPH0539226A (ja) | サイトメガロウイルス感染症用薬剤 | |
| JP2025502488A (ja) | イソキサゾリン誘導体を含む注射用製剤 | |
| CS265238B2 (en) | Method of injection applicable water solutions antimetic agent stabilization |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B1 | Patent granted (law 1993) | ||
| PUP | Patent expired |